Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Laura Nanni, Alessandro Broccoli, Cristina Nanni, Lisa Argnani, Michele Cavo & Pier Luigi Zinzani. (2018) Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report. Leukemia & Lymphoma 59:12, pages 2990-2993.
Read now
Read now
Paolo Anderlini, Rima M. Saliba, Celina Ledesma, Christina Chancoco, Amin M. Alousi, Elizabeth J. Shpall, Uday R. Popat, Chitra M. Hosing, Issa F. Khouri, Yago Nieto, Stefan Ciurea, Anas Younes, Michelle A. Fanale, Sandra Acholonu, Rosamar Valverde & Richard E. Champlin. (2012) Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leukemia & Lymphoma 53:3, pages 499-502.
Read now
Read now
Articles from other publishers (16)
Marco M.Z. Sharkawi, Norhan R. Mohamed, Mohammed T. El-Saadi & Noha H. Amin. (2023) Determination of Bendamustine, Gemcitabine and Vinorelbine (BEGEV) regimen in spiked human plasma using multivariate model update chemometric methods. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 299, pages 122836.
Crossref
Crossref
Marco M. Z. Sharkawi, Norhan R. Mohamed, Mohammed T. El-Saadi & Noha H. Amin. (2023)
Ecofriendly LC-MS/MS and TLC-densitometric methods for simultaneous quantitative assay and monitoring of BEGEV regimen,
in vivo
pharmacokinetic study application
. Analytical Methods 15:8, pages 1016-1027.
Crossref
Crossref
Maya Zlotnick, Abraham Avigdor, Elena Ribakovsky, Arnon Nagler & Meirav Kedmi. (2019) Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma. Acta Haematologica 141:2, pages 84-90.
Crossref
Crossref
Christian Gisselbrecht. (2016) Is nivolumab an option for Hodgkin's lymphoma?. The Lancet Oncology 17:9, pages 1183-1184.
Crossref
Crossref
Paolo Anderlini, Rima M. Saliba, Celina Ledesma, Tamera Plair, Amin M. Alousi, Chitra M. Hosing, Issa F. Khouri, Yago Nieto, Uday R. Popat, Elizabeth J. Shpall, Michelle A. Fanale, Frederick B. Hagemeister, Yasuhiro Oki, Saatva Neelapu, Jorge E. Romaguera, Anas Younes & Richard E. Champlin. (2016) Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell?Transplantation for Relapsed and Refractory Hodgkin?Lymphoma. Biology of Blood and Marrow Transplantation 22:7, pages 1333-1337.
Crossref
Crossref
Muhammad Shahzad Rauf, Irfan Maghfoor, Tusneem Ahmed M. Elhassan & Saad Akhtar. (2014) High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin’s lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy. Medical Oncology 32:1.
Crossref
Crossref
Adam Jona, Peter Szodoray & Arpad Illés. (2013) Immunologic pathomechanism of Hodgkin's lymphoma. Experimental Hematology 41:12, pages 995-1004.
Crossref
Crossref
Sally Moore, Irfan Kayani, Karl Peggs, Wendi Qian, Lisa Lowry, Kirsty Thomson, David C. Linch & Kirit Ardeshna. (2012)
Mini‐
BEAM
is effective as a bridge to transplantation in patients with refractory or relapsed
H
odgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage‐refractory
DLBCL
. British Journal of Haematology 157:5, pages 543-552.
Crossref
Crossref
Elif Suyanı, Gülsan Türköz Sucak, Şahika Zeynep Akı, Zeynep Arzu Yeğin, Zübeyde Nur Özkurt & Münci Yağcı. (2010) Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Annals of Hematology 90:6, pages 685-691.
Crossref
Crossref
Christian SteidlJoseph M. ConnorsRandy D. Gascoyne. (2011) Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment. Journal of Clinical Oncology 29:14, pages 1812-1826.
Crossref
Crossref
Martin A. Walter, Isabel J. Hildebrandt, Katrin Hacke, Adam L. Kesner, Owen Kelly, Gregory W. Lawson, Michael E. Phelps, Johannes Czernin, Wolfgang A. Weber & Robert H. Schiestl. (2010)
Small-Animal PET/CT for Monitoring the Development and Response to Chemotherapy of Thymic Lymphoma in
Trp53
−/−
Mice
. Journal of Nuclear Medicine 51:8, pages 1285-1292.
Crossref
Crossref
Yasuhiro Oki & Anas Younes. (2010) Does Rituximab Have a Place in Treating Classic Hodgkin Lymphoma?. Current Hematologic Malignancy Reports 5:3, pages 135-139.
Crossref
Crossref
Donatella Aldinucci, Annunziata Gloghini, Antonio Pinto, Rosaria De Filippi & Antonino Carbone. (2010) The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. The Journal of Pathology 221:3, pages 248-263.
Crossref
Crossref
Sung Yong Oh, Won Seog Kim, Dae Ho Lee, Seok Jin Kim, Sung Hyun Kim, Baek Yeol Ryoo, Hye Jin Kang, Young Jin Choi, Joo Seop Chung, Hyo Jung Kim & Cheolwon Suh. (2009) Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Investigational New Drugs 28:2, pages 171-177.
Crossref
Crossref
Claire Roddie & Karl S. Peggs. (2009) Hodgkin’s lymphoma. Medicine 37:4, pages 208-211.
Crossref
Crossref
Jia-Hong Chen, Ping-Ying Chang & Nai-Shun Yao. (2009) Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in advanced Hodgkin lymphoma. Hematology/Oncology and Stem Cell Therapy 2:2, pages 371-372.
Crossref
Crossref